KRKeith M. Rich

Keith M. Rich

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Keith M. Rich has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Neurofibromatosis Type 2: Natural History, Outcomes, and Treatment Patterns in a Large Contemporary Cohort

    by Brian A. Chu, Timothy E. Hullar, Albert H. Kim, Jonathan L. McJunkin, Gregory J. Zipfel, Keith M. Rich, Richard A. Chole, John G. Neely, Robert L. Grubb, Jian L. Campian, et al.

    Introduction: Neurofibromatosis type II (NF2) is a challenging inherited cancer condition, which predisposes patients to bilateral vestibular schwannomas, cranial and spinal meningiomas, spinal ependymomas and peripheral nerve schwannomas. A large contemporary cohort of patients with NF2 was reviewed to assess the impact of present-day therapies upon the natural history of this disease. Methods: A retrospective review of 54 patients with NF2 was performed using an IRB-approved brain tumor registry at Washington University in St. Louis over the last two decades. Data collection included demographics, age at diagnosis, burden of cranial and spinal disease, age at onset of deafness, treatments received (medical, surgical and radiation), and outcomes. Statistical analyses included a chi-square test used to compare early vs late age of diagnosis with respect to early vs late onset of unilateral deafness. Results: Median age at diagnosis was 17.5 years (range 3–65); average age at last follow-up was 31 years (range 3–69) for 25 males and 29 females. Of 48 patients who had spinal imaging done, tumors were found in the cervical spine (85.4%), thoracic spine (72.9%), lumbar spine (81.3%), and throughout the spine (60.4%). Median lifetime tumor burden during the time period tracked for this cohort of patient was 6 (range 2–25) intracranial tumors and 6.5 (range 0–32) spinal tumors. The number of spinal tumors likely represents a conservative estimate of small spinal tumors, as many were “too numerous to count.” The median number of lifetime medical and surgical interventions to date related to NF2 was 5 (range 0–17), surgical interventions 3 (range 0–17). The median number of surgical interventions per year was 0.1 (range 0–1.75). Fifteen individuals (27.8%) underwent radiosurgical treatment (9 for meningiomas, 8 for vestibular schwannomas, 3 for both, 2 for other cranial schwannomas, and 2 for spinal tumors). Eleven (20.4%) received bevacizumab (Avastin), an intravenous antibody to vascular endothelial growth factor (VEGF) therapy, two (3.4%) received everolimus (Afinitor), and one (1.9%) received panzopanib (Votrient). Median duration of medical therapy was 16.5 months (range 3–58, n = 12). Four (7.4%) died due to progressive disease or complications of treatment; median age at death was 26.5 years (range 4–38). Median age of onset of unilateral deafness, Gardener-Robertson class 3 or higher, was 21 years (range 7–56, n = 31); median age of bilateral deafness was 24 years (range 13–61, n = 15). Using a chi-square test (p < .001), it was determined that patients diagnosed with NF2 at an early age (<=20 years) had earlier onset of unilateral deafness (median age 15, range 7–20), compared with those diagnosed at a later age (unilateral deafness in latter group at median age 31, range 21–56) Conclusion: NF2 is a complex tumor predisposition disorder associated with bilateral vestibular schwannomas and numerous other tumors of the nervous system. NF2 patients typically undergo large numbers of surgical interventions and other treatments with an increasing number undergoing medical treatment such as bevacizumab in recent years. Patients diagnosed at a younger age are more likely to have an earlier age of onset of unilateral deafness.

  • Open Access

    Perilesional edema in radiation necrosis reflects axonal degeneration

    by Carlos J Perez-Torres, Liya Yuan, Robert E Schmidt, Keith M Rich, Joseph Jh Ackerman, Joel R Garbow

    Recently, we characterized a Gamma Knife® radiation necrosis mouse model with various magnetic resonance imaging (MRI) protocols to identify biomarkers useful in differentiation from tumors. Though the irradiation was focal to one hemisphere, a contralateral injury was observed that appeared to be localized in the white matter only. Interestingly, this injury was identifiable in T2-weighted images, apparent diffusion coefficient (ADC), and magnetization transfer ratio (MTR) maps, but not on post-contrast T1-weighted images. This observation of edema independent of vascular changes is akin to the perilesional edema seen in clinical radiation necrosis. The pathology underlying the observed white-matter MRI changes was explored by performing immunohistochemistry for healthy axons and myelin. The presence of both healthy axons and myelin was reduced in the contralateral white-matter lesion. Based on our immunohistochemical findings, the contralateral white-matter injury is most likely due to axonal degeneration.


  • Open Access

    A retrospective analysis of survival and prognostic factors after stereotactic radiosurgery for aggressive meningiomas

    by Daniel J Ferraro, Ryan K Funk, John William Blackett, Michelle R Ju, Todd A DeWees, Michael R Chicoine, Joshua L Dowling, Keith M Rich, Robert E Drzymala, Imran Zoberi, et al.

    While most meningiomas are benign, aggressive meningiomas are associated with high levels of recurrence and mortality. A single institution’s Gamma Knife radiosurgical experience with atypical and malignant meningiomas is presented, stratified by the most recent WHO classification.


  • Open Access

    Survival following gamma knife radiosurgery for brain metastasis from breast cancer

    by Jerry J Jaboin, Daniel J Ferraro, Todd A DeWees, Keith M Rich, Michael R Chicoine, Joshua L Dowling, David B Mansur, Robert E Drzymala, Joseph R Simpson, William J Magnuson, et al.

    Background: Breast cancer is the second most common cause of brain metastases in the United States. Although breast cancer induced brain metastases represent an incurable condition, some patients experience prolonged survival. In this retrospective study, we examine a cohort of patients with brain metastases from breast cancer treated with Gamma Knife stereotactic radiosurgery to identify factors that predict better outcomes. Methods: A retrospective database of 100 patients treated for brain metastases due to breast cancer via Gamma Knife radiosurgery (GKS) from July 1998 through March 2009 was reviewed. Patients who received radiosurgery as sole treatment, as a planned boost after whole brain radiotherapy or surgical resection, or as salvage after prior whole brain radiation therapy (WBRT) or surgical resection were included. Prognostic factors identified to be significant for survival in previous brain metastasis studies were analyzed for significance by univariate and multivariate Cox analysis. Results: Overall, the median brain progression-free survival time was 7.1 months and the median survival time was 12.3 months. No prognostic variables were significant for brain progression-free survival. For patients treated with a planned GKS after WBRT, GKS as sole treatment, GKS salvage after WBRT, GKS boost after surgery, or GKS for surgical salvage the median survival times (MSTs) were as follows: 12.2 months, 12.4 months, 9.5 months, 27.6 months and 33.4 months respectively. Differences between the groups were not significant (p = 0.06); however, GKS boost after surgery and GKS for salvage after surgery did have a trend toward better overall survival. The MST for patients of age 3 lesions had a MST of 5.9 months, which was significantly worse. Breast cancer subtype as approximated by biomarkers and KPS were not significant predictors of overall survival and stage at initial diagnosis was inversely associated with survival. Conclusion: Stereotactic radiosurgery offers good local control and prolonged survival in selected patients. Age and number of lesions are strong predictors of overall survival.


  • Novel chemo-sensitizing agent, ERW1227B, impairs cellular motility and enhances cell death in glioblastomas

    by Liya Yuan, Tracy C. Holmes, R. Edward Watts, Chaitan Khosla, Tom J. Broekelmann, Robert Mecham, Hong Zheng, Enrique W. Izaguirre, Keith M. Rich


    • 24 September 2008
      • Vol. 105  (5) , 429-33

    Clinical management of frequently encountered brain tumors.

    by Michael R Chicoine, Keith M Rich

    This overview of commonly encountered brain tumors will concentrate on the three most common neoplasms that occur in adult medicine, e.g., gliomas, metastatic lesions, and meningiomas.